• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Trypanosomiasis - Pipeline Review, H2 2012 Product Image

Trypanosomiasis - Pipeline Review, H2 2012

  • Published: August 2012
  • 110 pages
  • Global Markets Direct

Trypanosomiasis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Trypanosomiasis - Pipeline Review, H2 2012', provides an overview of the Trypanosomiasis therapeutic pipeline. This report provides information on the therapeutic development for Trypanosomiasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Trypanosomiasis. 'Trypanosomiasis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Trypanosomiasis.
- A review of the Trypanosomiasis products under development by companies and universities/research institutes based on READ MORE >

2
List of Tables 8
List of Figures 9
Introduction 10
REPORT COVERAGE 10
Trypanosomiasis Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Trypanosomiasis 12
Trypanosomiasis Therapeutics under Development by Companies 14
Trypanosomiasis Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Trypanosomiasis Therapeutics – Products under Development by Companies 23
Trypanosomiasis Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Trypanosomiasis Therapeutics Development 27
Eisai Co., Ltd. 27
Merck Serono S.A. 28
iCo Therapeutics Inc. 29
MOLOGEN AG 30
Dafra Pharma International Ltd. 31
Anacor Pharmaceuticals, Inc. 32
aRigen Pharmaceuticals, Inc. 33
iBio, Inc. 34
PepTcell Limited 35
Trypanosomiasis – Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
E1224 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ARA-01 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Miltefosine For Leishmaniasis - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Miltefosine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Zitromax - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Miltefosine + Liposomal Amphotericin B - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AmBisome + Miltefosine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Amphotericin B Deoxycholate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Liposomal Amphotericin B + Miltefosine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Liposomal Amphotericin B + Paromomycin Sulfate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Paromomycin Sulfate + Miltefosine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Miltefosine + Paromomycin Sulfate - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Benznidazole - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Leish-111f + MPL-SE - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
AmBisome + Paromomycin Sulfate - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Pentostam - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Paromomycin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Paromomycin + Gentamicin - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Aluminum Hydroxide - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Aluminum Hydroxide - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
iCo-009 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Meglumine Antimoniate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
GMCSF + Antimony - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
LEISH-F2 + MPL-SE Vaccine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
AmBisome + Sodium Stibogluconate - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
AmBisome + Miltefosine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Miltefosine - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Miltefosine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
AN3520 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
SCYX-6759 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
MGN1331 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Glucantime - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Liposomal Azithromycin - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Trypanosomes vaccine - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Miltefosine - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
AN5568 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
T-Cell Vaccine For Chagas Disease - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Pentamidine - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
TcSP2 Recombinant Protein - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Oleylphosphocholine - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Trichloroacetic Acid - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Fexinidazole - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
AS605240 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 95
vaccine for Leishmania - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Trypanosomiasis Therapeutics – Drug Profile Updates 97
Trypanosomiasis Therapeutics – Discontinued Products 99
Trypanosomiasis Therapeutics - Dormant Products 100
Trypanosomiasis – Product Development Milestones 103
Featured News & Press Releases 103
Mar 12, 2012: Anacor Announces Commencement Of Phase I Clinical Trials Of Boron-Based Compound For Sleeping Sickness 103
Mar 12, 2012: DNDi Receives €2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease 103
Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis 104
Feb 02, 2012: University Of Dundee Researchers Identify Potential New Treatment For Leishmaniasis 105
Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS 106
Jun 28, 2011: Anacor Pharmaceuticals Partnership Advances New Drug Candidate To Combat Sleeping Sickness 106
Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status 107
Apr 06, 2010: MOLOGEN AG Receives Funding To Develop A DNA Vaccine Against Hepatitis B 108
Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 110
Disclaimer 110

List of Tables
Number of Products Under Development for Trypanosomiasis, H2 2012 12
Products under Development for Trypanosomiasis – Comparative Analysis, H2 2012 13
Number of Products under Development by Companies, H2 2012 15
Number of Products under Investigation by Universities/Institutes, H2 2012 17
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 18
Comparative Analysis by Late Stage Development, H2 2012 19
Comparative Analysis by Mid Clinical Stage Development, H2 2012 20
Comparative Analysis by Early Clinical Stage Development, H2 2012 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 24
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 25
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 26
Eisai Co., Ltd., H2 2012 27
Merck Serono S.A., H2 2012 28
iCo Therapeutics Inc., H2 2012 29
MOLOGEN AG, H2 2012 30
Dafra Pharma International Ltd., H2 2012 31
Anacor Pharmaceuticals, Inc., H2 2012 32
aRigen Pharmaceuticals, Inc., H2 2012 33
iBio, Inc., H2 2012 34
PepTcell Limited, H2 2012 35
Assessment by Monotherapy Products, H2 2012 36
Assessment by Combination Products, H2 2012 37
Assessment by Stage and Route of Administration, H2 2012 39
Assessment by Stage and Molecule Type, H2 2012 41
Trypanosomiasis Therapeutics – Drug Profile Updates 97
Trypanosomiasis Therapeutics – Discontinued Products 99
Trypanosomiasis Therapeutics – Dormant Products 100
Trypanosomiasis Therapeutics – Dormant Products (Contd..1) 101
Trypanosomiasis Therapeutics – Dormant Products (Contd..2) 102

List of Figures
Number of Products under Development for Trypanosomiasis, H2 2012 12
Products under Development for Trypanosomiasis – Comparative Analysis, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 19
Mid Clinical Stage Products, H2 2012 20
Early Clinical Stage Products, H2 2012 21
Discovery and Pre-Clinical Stage Products, H2 2012 22
Assessment by Monotherapy Products, H2 2012 36
Assessment by Combination Products, H2 2012 37
Assessment by Route of Administration, H2 2012 38
Assessment by Stage and Route of Administration, H2 2012 39
Assessment by Molecule Type, H2 2012 40
Assessment by Stage and Molecule Type, H2 2012 41

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos